Zurich Cantonal Bank’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.06M Buy
31,355
+10,434
+50% +$344K ﹤0.01% 1524
2026
Q1
$670K Buy
+20,921
New +$681K ﹤0.01% 1657
2025
Q4
Sell
-7,404
Closed -$269K 3155
2025
Q3
$211K Sell
7,404
-136
-2% -$3.26K ﹤0.01% 2168
2025
Q2
$137K Buy
7,540
+1,550
+26% +$28.3K ﹤0.01% 2287
2025
Q1
$123K Buy
5,990
+3,390
+130% +$75.4K ﹤0.01% 2319
2024
Q4
$66.8K Buy
+2,600
New +$55.2K ﹤0.01% 2524

Other funds holding NAMS

Zurich Cantonal Bank's NAMS Position: Q2 2026 in Review

Zurich Cantonal Bank increased its NewAmsterdam Pharma (NAMS) stake by 50% in Q2 2026, buying an estimated $344K and bringing the position to 31,355 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

Zurich Cantonal Bank first reported a position in NAMS in Q4 2024 and has held it in 6 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Zurich Cantonal Bank held 31,355 shares of NewAmsterdam Pharma worth $1.06M as of Q2 2026.
  • Zurich Cantonal Bank bought 10,434 NewAmsterdam Pharma shares in Q2 2026, an estimated $344K.
  • NewAmsterdam Pharma made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1524 holding.
  • Zurich Cantonal Bank first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 6 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.